PEDIATRIC BLOOD & CANCER是一本专注于儿科血液学和肿瘤学研究的国际期刊，ISSN号为1545-5009，由Wiley出版商出版，出版地为美国，出版周期为月刊。该期刊的影响因子根据年份不同有所波动，近年来保持在2-3左右，属于SCI收录期刊，中科院分区通常位于医学大类3区或4区，具体分区需参考当年数据，该期刊为非开放获取（非OA）期刊。杂志的发文特点集中于儿童血液疾病和癌症的临床与基础研究，涵盖白血病、淋巴瘤、实体瘤、造血干细胞移植、遗传性血液病等领域，注重多学科交叉研究和临床实践应用。杂志质量在儿科血液肿瘤领域具有一定影响力，审稿流程较为严格，但影响因子相对中等，可能存在投稿竞争激烈或审稿周期较长的风险，适合从事儿科血液肿瘤研究的学者投稿。
Paternal Contributions to Biopsychosocial Outcomes of Children With Cancer: A Scoping Review
2025-05-08T03:31:07Z
Disseminated Infection Following the Administration of the Varicella Vaccine in a Child with Acute Lymphoblastic Leukemia
2025-05-08T03:23:56Z
Clinical Practice Guideline for the Management of Communication and Swallowing in Children Diagnosed With Childhood Brain Tumor or Leukemia
2025-05-07T03:48:36Z
Inequities in Pediatric Cancer: Unveiling the Impact of Social Determinants of Health on Survival
2025-05-07T04:39:05Z
Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs
2025-05-06T04:18:48Z
User Perceptions of a Multilevel mHealth Intervention to Boost Adherence to Hydroxyurea in Sickle Cell Disease
2025-05-06T04:24:14Z
Sickle Cell Story Club: Implementation of a Clinic‐Based Literacy Promotion Program
2025-05-06T04:30:21Z
Rare Findings of Spleen Lesions Secondary to Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Children
2025-05-05T04:43:46Z
Twenty Years of the Paediatric Radiation Oncology Society
2025-05-05T04:54:08Z
Letter to the Editor: Proton Therapy for Locally Advanced Unresectable Ameloblastoma in a Child
2025-05-05T04:50:09Z
Recurrent Immune‐Effector Cell‐Associated Neurotoxicity Syndrome with Atypical Manifestations after Tisagenlecleucel
2025-05-05T04:50:29Z
A Rare Intersection: Wilms Tumor in a Patient with PIGO Syndrome
2025-05-05T04:40:13Z
Primary Cervical Clear Cell Adenocarcinoma in an Infant: A Rare Tumor in an Uncommon Site
2025-05-05T04:44:25Z
Comment on: Use of Plerixafor for Short‐Term Management of Leukopenia in a Pediatric Patient With WHIM Syndrome
2025-05-05T04:39:46Z
Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease
2025-05-02T13:03:02Z
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
2025-05-02T12:20:33Z
